Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib + SOX as conversion therapy in borderline resectable gastric cancer
ChiCTR2600128652Phase 2Completed
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in gastric cancer (GC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: R0 resection rate. Started Jul 2026; status: completed.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2600128652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128652.